|
TA103 Etanercept ac efalizumab i drin soriasis: deall canllawiau NICE (fformat MS Word)
15 December 2009 (430 Kb 2 mins 5 sec) |
This page was last updated: 30 March 2010
Summaries of the best available evidence for selected new medicines, or for existing medicines with new indications, to inform local NHS planning and decision-making.
A new service providing summaries of the best available evidence on selected unlicensed and off-label medicines, designed to meet demand for information to inform local NHS planning and decision-making.
Advice to support best practice in medicines management and use in the NHS, including good practice guides on developing local medicines formularies.
Medicines evidence commentaries - Losartan or Candesartan in heart failure; Metformin in type 2 diabetes.
Evidence summaries: new medicines - Fidaxomicin for Clostridium difficile infection
Evidence summaries: unlicensed and off-label medicines - tranexamic acid for major haemorrhage
Our programme of national events for medicines managers and prescribers, free of charge for NHS staff in England.
Support for communities of practice including controlled drugs, new medicines, local decision making and medicines and prescribing trainers and facilitators.
Sign up for and manage your subscriptions for a range of medicines and prescribing bulletins and alerts.
NICE is responsible for providing access for the NHS to the British National Formulary.
